Alpine Immune Sciences (NASDAQ:ALPN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The brokerage presently has a $4.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 11.24% from the stock’s current price.
According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “
Other research analysts have also recently issued reports about the stock. Oppenheimer set a $13.00 price target on shares of Alpine Immune Sciences and gave the stock a “buy” rating in a report on Tuesday, March 19th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $11.15.
Alpine Immune Sciences stock traded up $0.03 during midday trading on Tuesday, hitting $4.27. 400 shares of the stock were exchanged, compared to its average volume of 12,852. Alpine Immune Sciences has a 52-week low of $3.66 and a 52-week high of $8.59. The company has a market capitalization of $79.11 million, a PE ratio of -1.62 and a beta of 1.89. The stock’s 50-day simple moving average is $4.47. The company has a quick ratio of 7.33, a current ratio of 7.33 and a debt-to-equity ratio of 0.03.
Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.01). As a group, analysts predict that Alpine Immune Sciences will post -2.67 EPS for the current year.
In other news, VP James Paul Rickey purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The shares were acquired at an average cost of $4.95 per share, for a total transaction of $49,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 75.10% of the stock is currently owned by insiders.
An institutional investor recently bought a new position in Alpine Immune Sciences stock. Leonard Rickey Investment Advisors P.L.L.C. bought a new stake in Alpine Immune Sciences Inc (NASDAQ:ALPN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $42,000. Leonard Rickey Investment Advisors P.L.L.C. owned approximately 0.05% of Alpine Immune Sciences at the end of the most recent reporting period. 47.04% of the stock is owned by hedge funds and other institutional investors.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
Recommended Story: Do Tariffs Work?
Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.